Sensus Healthcare’s (SRTS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Sensus Healthcare (NASDAQ:SRTS) in a research note issued to investors on Monday morning, AnalystRatings.com reports. HC Wainwright currently has a $9.00 target price on the stock.

“Our price target is derived from an EV-to-sales multiple of 6.0x and TTM revenue ($1.57/share). Risks include, but are not limited to: (1) failure of SRT and IORT systems to achieve commercial success due to reimbursement, penetration rate, and/or competition; (2) failure of other potential pipeline products; and (3) potential dilution risk. Sensus Healthcare, Inc. May 13, 2019 H.C. WAINWRIGHT & CO.”,” the firm’s analyst commented.

Several other brokerages have also recently commented on SRTS. ValuEngine cut shares of Sensus Healthcare from a buy rating to a hold rating in a research note on Wednesday, May 1st. Maxim Group reaffirmed a buy rating and set a $11.00 price objective on shares of Sensus Healthcare in a research note on Friday, May 10th. Roth Capital reaffirmed a buy rating on shares of Sensus Healthcare in a research note on Tuesday, February 19th. TheStreet raised shares of Sensus Healthcare from a d rating to a c rating in a research note on Thursday, February 14th. Finally, Alliance Global Partners cut shares of Sensus Healthcare from a buy rating to a neutral rating in a research note on Friday, May 10th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of $10.32.

SRTS opened at $5.49 on Monday. The stock has a market capitalization of $90.68 million, a PE ratio of -39.21 and a beta of -0.53. Sensus Healthcare has a twelve month low of $5.22 and a twelve month high of $9.23.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.11). The firm had revenue of $5.44 million for the quarter, compared to analysts’ expectations of $7.81 million. Sensus Healthcare had a negative net margin of 11.65% and a negative return on equity of 14.30%.

In related news, EVP Richard Golin sold 5,943 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The shares were sold at an average price of $7.56, for a total transaction of $44,929.08. Following the completion of the transaction, the executive vice president now owns 925,237 shares of the company’s stock, valued at $6,994,791.72. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In the last ninety days, insiders have sold 7,203 shares of company stock valued at $54,379. 31.20% of the stock is owned by corporate insiders.

A number of large investors have recently modified their holdings of the stock. Northern Trust Corp bought a new stake in Sensus Healthcare during the fourth quarter valued at approximately $86,000. BerganKDV Wealth Management LLC bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $88,000. ExodusPoint Capital Management LP bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $106,000. Spark Investment Management LLC bought a new stake in shares of Sensus Healthcare in the 1st quarter worth approximately $155,000. Finally, BlackRock Inc. lifted its holdings in shares of Sensus Healthcare by 10.2% in the 4th quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock worth $192,000 after acquiring an additional 2,418 shares during the last quarter. 7.13% of the stock is owned by institutional investors.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.

Featured Story: How accurate is the Rule of 72?

Analyst Recommendations for Sensus Healthcare (NASDAQ:SRTS)

Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.